Crestline Management LP Takes $332,000 Position in Penumbra, Inc. (NYSE:PEN)

Crestline Management LP purchased a new stake in Penumbra, Inc. (NYSE:PEN - Free Report) in the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm purchased 1,400 shares of the company's stock, valued at approximately $332,000.

Other large investors have also recently added to or reduced their stakes in the company. Barclays PLC lifted its stake in shares of Penumbra by 16.5% during the 3rd quarter. Barclays PLC now owns 18,025 shares of the company's stock worth $3,502,000 after buying an additional 2,559 shares during the last quarter. GAMMA Investing LLC lifted its stake in shares of Penumbra by 160.8% during the 4th quarter. GAMMA Investing LLC now owns 446 shares of the company's stock worth $106,000 after buying an additional 275 shares during the last quarter. Pallas Capital Advisors LLC lifted its stake in shares of Penumbra by 3.8% during the 4th quarter. Pallas Capital Advisors LLC now owns 1,108 shares of the company's stock worth $263,000 after buying an additional 41 shares during the last quarter. Park Avenue Securities LLC lifted its stake in shares of Penumbra by 18.6% during the 4th quarter. Park Avenue Securities LLC now owns 1,665 shares of the company's stock worth $395,000 after buying an additional 261 shares during the last quarter. Finally, Diversify Wealth Management LLC lifted its stake in shares of Penumbra by 36.3% during the 4th quarter. Diversify Wealth Management LLC now owns 1,645 shares of the company's stock worth $412,000 after buying an additional 438 shares during the last quarter. Institutional investors and hedge funds own 88.88% of the company's stock.

Penumbra Price Performance

NYSE PEN traded up $3.18 during trading hours on Friday, reaching $278.50. The company's stock had a trading volume of 346,391 shares, compared to its average volume of 437,583. The firm's 50-day moving average price is $279.00 and its 200-day moving average price is $262.86. The company has a quick ratio of 3.25, a current ratio of 6.01 and a debt-to-equity ratio of 0.02. Penumbra, Inc. has a 1 year low of $148.00 and a 1 year high of $310.00. The company has a market capitalization of $10.79 billion, a price-to-earnings ratio of 819.58, a PEG ratio of 2.83 and a beta of 0.53.

Penumbra (NYSE:PEN - Get Free Report) last issued its quarterly earnings data on Wednesday, April 23rd. The company reported $0.83 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.66 by $0.17. The business had revenue of $324.14 million for the quarter, compared to analysts' expectations of $315.72 million. Penumbra had a return on equity of 9.74% and a net margin of 1.17%. The company's revenue for the quarter was up 16.3% on a year-over-year basis. During the same period in the prior year, the firm earned $0.41 EPS. On average, equities research analysts predict that Penumbra, Inc. will post 3.67 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on PEN shares. Morgan Stanley raised their price target on shares of Penumbra from $240.00 to $260.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 19th. Canaccord Genuity Group raised their target price on shares of Penumbra from $323.00 to $340.00 and gave the company a "buy" rating in a report on Wednesday, February 19th. BTIG Research reissued a "buy" rating on shares of Penumbra in a report on Thursday, April 24th. Needham & Company LLC reissued a "hold" rating on shares of Penumbra in a report on Wednesday, February 19th. Finally, Wells Fargo & Company raised their target price on shares of Penumbra from $305.00 to $315.00 and gave the company an "overweight" rating in a report on Thursday, April 24th. Three analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $302.40.

Insider Buying and Selling at Penumbra

In related news, Director Thomas Wilder sold 360 shares of the company's stock in a transaction on Monday, March 31st. The stock was sold at an average price of $264.58, for a total transaction of $95,248.80. Following the completion of the sale, the director now directly owns 4,533 shares in the company, valued at $1,199,341.14. This represents a 7.36% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, CAO Lambert Shiu sold 501 shares of the stock in a transaction dated Tuesday, March 4th. The shares were sold at an average price of $282.88, for a total value of $141,722.88. Following the completion of the sale, the chief accounting officer now owns 32,969 shares of the company's stock, valued at approximately $9,326,270.72. This trade represents a 1.50% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 159,996 shares of company stock valued at $45,228,678 in the last quarter. 4.20% of the stock is owned by insiders.

Penumbra Profile

Penumbra, Inc, together with its subsidiaries, designs, develops, manufactures, and markets medical devices in the United States and internationally. The company offers peripheral products, including the Indigo System for power aspiration of thrombus in the body; Lightning Flash, a mechanical thrombectomy system; Lightning Bolt 7, an arterial thrombectomy system; and CAT RX.